BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Viteava Pharmaceuticals Announces Research Agreement With McGill University And Leveraging Of Federal Grants


1/28/2014 11:38:45 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TORONTO
, Jan. 28, 2014 /PRNewswire-iReach/ -- Viteava Pharmaceuticals Inc. announced the execution of a sponsored research agreement with McGill University relating to novel analogs and derivatives of the green tea flavonoid, (-)epigallocatechin-3-gallate (EGCG). Matching funds have been received from the Canadian Institutes of Health Research Proof of Principle Phase II (CIHR POPII) program. Professor Tak-Hang Chan of McGill University is the Principal Investigator with collaboration from Viteava Pharmaceuticals, as well as Professor Q. Ping Dou of Wayne State University and the Karmanos Cancer Institute. Professor Chan was the only successful recipient of funding under the Fall 2011 competition of the CIHR POPII program.

(Photo: http://photos.prnewswire.com/prnh/20140128/MN52741)

"Competitive grants such as the CIHR POPII program provide important validation for the potential importance of this class of drug candidates, and represent a source of funding that is a life-line for start-up companies," said Robert Foldes, Viteava's founder and CEO.

This research agreement focuses on the preclinical development of VPE001, a proprietary prodrug of EGCG, as well as additional characterization in animal models of cancer. The funding will also be used to characterize and optimize the synthesis of two back-up drug candidates. "We are grateful to CIHR for their support, as this funding is critical for helping us to advance VPE001 much closer to initiating human clinical studies," said Professor Chan.

Viteava also announced funding support from VentureStart (http://venturestart.riccentre.ca/), a program that provides services and matching funds for qualified entrepreneurs in southern Ontario. Coordinated by the RIC Centre, VentureStart received $7.5 million through Federal Economic Development Agency for Southern Ontario (FedDev Ontario). The program is delivered by the regional innovation centres in the Ontario Network of Entrepreneurs (ONE). Through this program, Viteava also receives business support and mentoring through an executive in residence at MaRS (http://www.marsdd.com/).

About Viteava Pharmaceuticals Inc.

Viteava is a start-up drug development company dedicated to improving the treatment and management of cancer and related conditions to enhance quality of life. It is a world leader in the chemistry and biology of small molecule analogs and derivatives related to the green tea flavonoid, (-)epigallocatechin-3-gallate (EGCG). Its mission is to leverage the growing body of positive human clinical data with green tea extracts, to develop novel chemical entities with enhanced potency and bioavailability, ideally suited to early intervention in the treatment and management of cancer and related conditions. It has identified VPE001, a prodrug of EGCG with improved bioavailability and potency, as its lead drug candidate expected to enter clinical development in 2015. Initial clinical indications may include the treatment of symptomatic uterine fibroids and/or delaying the progression of cancer in high-risk patients.

For more information visit: http://www.viteava.com.

Media Contact:Robert Foldes, Viteava Pharmaceuticals Inc., 416-817-0745, robert@viteava.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Viteava Pharmaceuticals Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES